Primary Experience with Oxaliplatin Chemotherapy for Recurrent and/or Metastatic Colorectal Cancer.
- Author:
Sung Gwan KANG
1
;
Byung No BAE
;
Gee Hwan KIM
;
Se Hwan HAN
;
Hong Joo KIM
;
Yung Duck KIM
;
Hong Yong KIM
Author Information
1. Department of Surgery, Inje University College of Medicine, Sang Gye Paik Hopsital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Advanced colorectal cancer;
Oxaliplatin chemotherapy;
Side effect
- MeSH:
Aged;
Anemia;
Cisplatin;
Colorectal Neoplasms*;
Diagnosis;
Diarrhea;
Drug Therapy*;
Female;
Follow-Up Studies;
Humans;
Leukopenia;
Male;
Nausea;
Neoplasm Staging;
Neutropenia;
Stomatitis;
Thrombocytopenia;
Vomiting
- From:Journal of the Korean Surgical Society
2000;59(5):621-626
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: In the past 30 years, the chemotherapeutic approach to advanced colorectal cancer has remained major challenge. Fluorinated pyrimidine has been the main active drugs, and cisplatin was introduced under clinical conditions. Because of the renal and hematologic toxicity of cisplatin, oxaliplatin was developed. The purpose of this study was to assess the clinical response to and the side effects of oxaliplatin chemotherapy. METHODS: From January 1999, 11 patients who received oxaliplatin chemotherapy entered this study. There were 9 males and 2 females, and their ages varied from 40 to 71 years old. The mean ECOG scale was 1. According to TNM staging, 2 was stage 2 at diagnosis, 5 at stage 3, and 4 at stage 4. Totally, we performed 57 cycles of oxaliplatin chemotherapy. Labaratory data and toxicity were assessed for each cycle according to the WHO scale. Ten (10) patients have received follow-up CT since treatment. RESULTS: Grade 1 anemia occurred in 68% of the cycles, grade 2 in 20%, and grade 3 in 12%. Grade 1 thrombocytopenia occurred in 35% of the cycles and grade 2 in 14%. Grade 1 leukopenia and neutropenia occurred in 27% and 25% of the cycles, respectively. Grade 1 stomatitis occurred in 12% of the cycles and grade 2 in 2%. Grade 1 nausea occurred in 44% of the cycles. Grade 1 vomiting occurred in 14% of the cycles and grade 2 in 4%. Grade 1 diarrhea occurred in 10% of the cycles and grade 2 in 4%. Nephrotoxicity was absent, and typical oxaliplatin neurotoxicity was reported as grade 1 in 2% of the cycles. No complete response was observed, and oxaliplatin che motherapy induced one partial remission. CONCLUSION: There was a mild hematologic and alimentary side effect. There were no renal and few neurologic side effects, but the response to oxaliplatin was poor.
